相关实验视频
Updated: Feb 20, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.4K
药剂师干预2型糖尿病高风险患者的安全处方:一项随机临床试验
Lisa K Gilliam1, Melissa M Parker2, Minnie W Chen1
1The Permanente Medical Group, South San Francisco Kaiser Medical Center, South San Francisco, California.
JAMA network open
|February 18, 2026
概括
临床药剂师外展显著改善了2型糖尿病 (T2D) 的高风险患者的糖尿病药物安全性,减少了低血糖事件而不会恶化血糖控制. 这种主动的方法提高了患者的安全性.
科学领域:
- 临床药房 临床药房
- 糖尿病管理 糖尿病管理
- 患者安全 患者安全
背景情况:
- 严重的低血糖是糖尿病药物的危险并发症,增加了跌倒,心血管事件,认知能力下降和死亡的风险.
- 在2型糖尿病 (T2D) 患者中识别和减轻低血糖风险对于改善患者的治疗结果和减少医疗负担至关重要.
研究的目的:
- 评估使用基于证据的低血糖预防算法推广更安全的糖尿病处方的积极临床药剂师推广的有效性.
- 确定这种干预措施是否能降低高风险T2D患者严重低血糖的风险.
主要方法:
- 一项随机临床试验,涉及200名患有T2D的高危低血糖症的成年人.
- 参与者被随机分配到临床药剂师外展干预组或常规护理控制组.
- 衡量的主要结局是指那些接受了更安全的糖尿病治疗方案的患者比例,其定义是停止使用硫基尿素和/或特定类型的胰岛素.
主要成果:
- 与对照组相比,干预组的患者被处方更安全的糖尿病治疗方案的可能性要大得多 (28.1%对比15.8%).
- 干预组经历了较少的低血糖相关的急诊室或住院患者遭遇 (0对5.3%).
- 在干预组中没有观察到血红蛋白A1c (HbA1c) 控制的显著恶化.
结论:
- 积极的,以协议为导向的临床药剂师外展,集成到基于团队的护理中,改善了T2D管理中的药物优化和患者安全.
- 这种基于证据的策略有效地降低了高风险个体严重低血糖的风险,提高了患者的整体幸福感.
- 该干预措施显示出降低与低血糖相关事件相关的医疗保健成本的潜力.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
702
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
702
01:22Diabetes Mellitus: Type 2 and Gestational
5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
752
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
752
01:16Insulin: Dosing Regimen and Adverse Effects
874
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
874
01:15Drug Dosing: Geriatric Patients
289
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
289